Clinical trials: Elevated Intraocular Pressure
Renal Insufficiency, Chronic, Glaucoma
Intraocular Pressure and Hemodialysis Midwestern Brazil
Objective: To evaluate the variation in intraocular pressure in patients with chronic kidney disease, according to the time interval between hemodialysis sessions and to the influence of weight and blood pressure on intraocular…
- Trial name
- EHPIOBRAZIL (NCT02405884)
- Testing
- Kowa HA-2 Perkins applanation tonometer.
- Volunteers
- 39 people
- Sponsor
- VER Excelência em Oftalmologia
Open-Angle Glaucoma, Ocular Hypertension
Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular…
- Trial name
- NCT00465621
- Testing
- Xalatan
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Alcon Research
Cataract, Glaucoma
Effect of Yellow-Tinted Intraocular Lens on Standard Automated Perimetry (SAP) and Short-wavelength Automated Perimetry (SWAP) in Patients With and Without Glaucoma
To investigate the effect of yellow-tinted IOLs on the Short Wave-length Automated Perimetry (SWAP) and Standard Automated Perimetry (SAP) in patients with and without glaucoma.
- Trial name
- NCT01305616
- Testing
- Phacoemulsification with yellow-tinted intraocular lens
- Where
- Iran
- Volunteers
- 34 people
- Sponsor
- Rassoul Akram Hospital
Glaucoma
The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants
The purpose of this study is to compare the post-operative complication rates and surgical outcomes in patients with a Baerveldt 350 implant following scheduled rip-cord removal in clinic at post-operative week 3 versus…
- Trial name
- NCT01915706
- Testing
- Ripcord removal
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- Duke University
Primary Open Angle Glaucoma
A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab interno (inside the eye) and ab…
- Trial name
- NCT06822738
- Testing
- XEN63 Glaucoma Treatment System
- Where
- 29 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Primary Open Angle Glaucoma, Ocular Hypertension
Direct Selective Laser Trabeculoplasty in Ethnic Chinese Population
The objective of this study is to evaluate the safety and effectiveness of Direct Selective Laser Trabeculoplasty (DSLT) in ethnic Chinese participants with Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT), or Normal…
- Conditions
- Primary Open Angle Glaucoma, Ocular Hypertension, Normal Tension Glaucoma
- Trial name
- Zhuiguangzhe (NCT05902871)
- Testing
- External Automatic Glaucoma Laser, Direct Selective Laser Trabeculoplasty
- Where
- 2 sites in China, Singapore
- Volunteers
- 40 people
- Sponsor
- BelkinVision
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Community Based Treatment for (ComBaT) Glaucoma
The purpose of this research is to evaluate if intervention and education can change the behavior of someone's willingness to see an eye care provider to prevent blindness and glaucoma.
- Trial name
- NCT06124521
- Testing
- ComBaT Glaucoma
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Michigan
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Angle-Closure Glaucoma
Research on the Diagnosis and Treatment of Angle Closure Glaucoma With Abnormal Lens Zonular
Angle-closure glaucoma is the main type of glaucoma in China, which is divided into acute and chronic angle-closure glaucoma. Previous studies from our group have found that, in lens excision combined with glaucoma surgery…
- Trial name
- NCT05163093
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Chunyan Qiao_2021
Glaucoma, Open-Angle
Visual Field Defect Estimation Using Sequentially Optimized Reconstruction Strategy on Healthy and Glaucoma Subjects
Perimetry is a well-established method that is used to measure the visual field functions of humans. Commercially available products, such as the OCTOPUS 900 (Haag-Streit AG, Koeniz, Switzerland), are commonly used for assessing…
- Trial name
- NCT03325751
- Testing
- Visual field testing
- Where
- Switzerland
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Open Angle Glaucoma, Ocular Hypertension
Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
Test ocular hypotensive efficacy and systemic safety of netarsudil 0.01%, 0.02%, 0.04% relative to placebo in subjects with open-angle glaucoma or ocular hypertension in Japan
- Trial name
- NCT03844945
- Testing
- Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%
- Where
- 25 sites in Japan
- Volunteers
- 215 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Open-Angle, Normal Tension Glaucoma
Investigation of Neurovascular Coupling in Glaucoma Patients and Healthy Subjects
Glaucoma is characterized by a progressive loss of retinal ganglion cells (RGCs) leading to optic nerve head (ONH) damage and associated visual field defects.
- Conditions
- Glaucoma, Open-Angle, Normal Tension Glaucoma, Ocular Hypertension
- Trial name
- NCT03870230
- Testing
- Fourier Domain Doppler Optical Coherence Tomography (FDOCT), Dynamic Vessel Analyzer (DVA), Pattern Electroretinography (pERG)
- Where
- Austria
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Glaucoma, Ocular Hypertension
Non-Interventional Study In Patients With Ocular Hypertension And Open Angle Glaucoma Treated With Xalatan And Xalacom
Non-interventional study to obtain real life data from the treatment with Xalatan and Xalacom in Germany and to assess the long-term efficacy and tolerability under routine conditions.
- Trial name
- XCHANGE (NCT01012245)
- Testing
- no intervention
- Volunteers
- 28,812 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma
Functional and Structural Imaging for Glaucoma
The specific aims of the clinical studies are to: Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion.
- Trial name
- FSOCT (NCT01957267)
- Where
- United States
- Volunteers
- 249 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Glaucoma
Glaucoma Treatment by Circular Cyclocoagulation Using High Intensity Focused Ultrasound With the EYEOP Medical Device
The aim of the study is to evaluate the effectiveness and the safety of the EYEOP treatment using High Intensity Focused Ultrasound in refractory glaucoma patients.
- Trial name
- NCT01338467
- Testing
- EYEOP device
- Where
- 9 sites in France
- Volunteers
- 52 people
- Sponsor
- EyeTechCare
Ocular Hypertension, Glaucoma
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
This study will test the hypothesis that CF101, administered orally, will reduce intraocular pressure in patients with ocular hypertension and/or glaucoma.
- Trial name
- NCT01033422
- Testing
- CF101
- Where
- 3 sites in Bulgaria, Israel
- Volunteers
- 89 people
- Sponsor
- Can-Fite BioPharma
Glaucoma, Acupuncture
Acupuncture as Adjuvant Therapy for Glaucoma - Protocol for a Randomized Controlled Trial
This clinical trial used acupuncture as an adjunctive treatment for glaucoma patients. A randomized, controlled trial involving 50 subjects will be conducted and observed for 12 weeks to evaluate the clinical efficacy of…
- Conditions
- Glaucoma, Acupuncture, Intraocular Pressure
- Trial name
- NCT05753137
- Testing
- Acupuncture
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- China Medical University Hospital
Glaucoma
IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI
The purpose of the study is to determine the relationship of the intraocular pressure patterns recorded during 2 sessions using Triggerfish, before and after elective laser peripheral iridotomy in angle closure glaucoma patients
- Trial name
- NCT01906151
- Testing
- SENSIMED Triggerfish®
- Where
- France
- Sponsor
- Sensimed AG
Glaucoma, Open-Angle, Ocular Hypertension
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle…
- Trial name
- NCT05401357
- Testing
- Test - Bimatoprost 0.01% Ophthalmic Solution, Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)
- Where
- 9 sites in United States
- Volunteers
- 168 people
- Sponsor
- Amneal Pharmaceuticals, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.